TY - JOUR
T1 - Effect of using fidaxomicin on recurrent Clostridium difficile infection
AU - Biggs, Martin
AU - Iqbal, Tariq
AU - Holden, Elisabeth
AU - Clewer, Victoria
AU - Garvey, Mark I.
PY - 2019/6
Y1 - 2019/6
N2 - Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.
AB - Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.
KW - clostridium difficile
KW - recurrence
KW - fidaxomicin
UR - http://www.scopus.com/inward/record.url?scp=85061814186&partnerID=8YFLogxK
U2 - 10.1016/j.jhin.2018.12.018
DO - 10.1016/j.jhin.2018.12.018
M3 - Article
SN - 0195-6701
VL - 102
SP - 165
EP - 167
JO - The Journal of hospital infection
JF - The Journal of hospital infection
IS - 2
ER -